What's in Harmony Biosciences Management, Inc.'s pipeline?

Harmony Biosciences Management, Inc. has 6 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 2 in Phase 2, 1 in Phase 1.

Which companies overlap with Harmony Biosciences Management, Inc.'s portfolio?

Top competitors by shared drug class: Bioprojet.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/harmony-biosciences-management-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Harmony Biosciences Management, Inc. — Portfolio Competitive Intelligence Brief

Harmony Biosciences Management, Inc. pipeline: 0 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Open-label pitolisant	Open-label pitolisant	phase 3	Histamine H3 receptor antagonist	H3 receptor (histamine H3 receptor)	Neurology
Double-blind pitolisant	Double-blind pitolisant	phase 3	Histamine H3 receptor antagonist	H3 receptor	Neurology
Pitolisant tablet	Pitolisant tablet	phase 3	Histamine H3 receptor antagonist	H3 receptor	Neurology

Therapeutic area mix

Neurology · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bioprojet · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Harmony Biosciences Management, Inc.:

Cite this brief

Drug Landscape (2026). Harmony Biosciences Management, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/harmony-biosciences-management-inc. Accessed 2026-05-16.